Completed PHASE3 INTERVENTIONAL 1-arm NCT01333592

Long-term Study of KAD-1229 in Type 2 Diabetes Patients

A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy

Sponsor: Kissei Pharmaceutical Co., Ltd.

Conditions Type 2 Diabetes

Interventions KAD-1229

Updated 8 times since 2017 Last updated: Nov 27, 2014 Primary completion: Aug 31, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01333592, this PHASE3 trial focuses on Type 2 Diabetes and remains completed. Sponsored by Kissei Pharmaceutical Co., Ltd., it has been updated 8 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kissei Pharmaceutical Co., Ltd.

Data source: Kissei Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kanto Region, Chugoku Region, Kyushu Region, Japan